Reviewing ACADIA Pharmaceuticals Inc. (ACAD)’s and Amicus Therapeutics Inc. (NASDAQ:FOLD)’s results

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Amicus Therapeutics Inc. (NASDAQ:FOLD) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 27 22.13 N/A -2.09 0.00
Amicus Therapeutics Inc. 12 18.99 N/A -2.15 0.00

Table 1 highlights ACADIA Pharmaceuticals Inc. and Amicus Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 represents ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Amicus Therapeutics Inc. (NASDAQ:FOLD)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. 0.00% -79.7% -68.1%
Amicus Therapeutics Inc. 0.00% -94.9% -52.1%

Risk & Volatility

ACADIA Pharmaceuticals Inc. has a 2.81 beta, while its volatility is 181.00%, thus making it more volatile than Standard and Poor’s 500. Amicus Therapeutics Inc.’s 83.00% more volatile than Standard and Poor’s 500 which is a result of the 1.83 beta.


The Current Ratio and a Quick Ratio of ACADIA Pharmaceuticals Inc. are 6.4 and 6.3. Competitively, Amicus Therapeutics Inc. has 7.3 and 7.2 for Current and Quick Ratio. Amicus Therapeutics Inc.’s better ability to pay short and long-term obligations than ACADIA Pharmaceuticals Inc.

Analyst Ratings

ACADIA Pharmaceuticals Inc. and Amicus Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 1 3 2.75
Amicus Therapeutics Inc. 0 0 1 3.00

ACADIA Pharmaceuticals Inc.’s upside potential is 5.69% at a $42.75 average price target. Amicus Therapeutics Inc. on the other hand boasts of a $20 average price target and a 104.08% potential upside. The results from earlier shows that analysts view suggest that Amicus Therapeutics Inc. seems more appealing than ACADIA Pharmaceuticals Inc.

Insider and Institutional Ownership

ACADIA Pharmaceuticals Inc. and Amicus Therapeutics Inc. has shares owned by institutional investors as follows: 94.9% and 0%. 0.3% are ACADIA Pharmaceuticals Inc.’s share owned by insiders. Competitively, Amicus Therapeutics Inc. has 0.9% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. 6.82% -8.69% 3.89% 7.2% 65.97% 52.01%
Amicus Therapeutics Inc. -1.9% -0.4% -7.53% 6.26% -13.23% 29.44%

For the past year ACADIA Pharmaceuticals Inc. was more bullish than Amicus Therapeutics Inc.


ACADIA Pharmaceuticals Inc. beats Amicus Therapeutics Inc. on 5 of the 9 factors.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.